All articles by Chemistry World – Page 35
-
Business
Business roundup: May 2009
Sanofi splashes the cash in Latin America Sanofi aims to be South America’s number one Sanofi-Aventis has gone on a South American shopping spree, buying two generics companies within the space of a week - and in the process has become Latin America’s leading generics manufacturer. On ...
-
Podcast
April 2009
Chemistry World Podcast - April 2009 00:12 -- Introduction 02:11 -- Reading single strands of DNA, base by base 05:01 -- The new electrode material that promises speedy battery charging ...
-
Opinion
Letters: April 2009
As Matt Brown is a ’freelance science writer based in London,’ it is perhaps not surprising that he missed out on reporting the first new pharmacy degree in the UK for around 30 years - that of the School of Chemical Sciences and Pharmacy at the University of East Anglia ...
-
Business
Business roundup: April 2009
Merger goes ahead as Dow, Rohm and Haas settle dispute Dow Chemical has finally agreed to complete the acquisition of speciality materials firm Rohm and Haas in a $15.3 billion (?11 billion) deal after the two firms settled their dispute over the planned merger. The takeover, which will create the ...
-
News
First auto carbohydrate synthesiser
Scientists have unveiled the first fully automated carbohydrate synthesiser, hoped to speed vaccine development
-
Podcast
March 2009
Chemistry World Podcast - March 200900:12 -- Introduction02:03 -- Exercise capacity of heart failure patients improved 05:00 -- Molecular thermometer takes cell temperature 07:41 -- ...
-
Opinion
Letters: March 2009
I recently delivered an address at a presentation evening at a local school where I was introduced to the audience as an organic chemist. At the reception which followed, I was approached by a parent who congratulated me heartily on my lifestyle choice of being ’organic’ and I was asked ...
-
Business
Business roundup: March 2009
Pfizer’s Wyeth injection Source: © AP PHOTOS Jeffrey Kindler, Pfizer’s CEO, explains the merger Pfizer has agreed to pay $68 billion (?48.3 billion) for rival US biopharmaceutical firm Wyeth, gaining access to its rich product portfolio and promising pipeline of experimental drugs. Pfizer hopes Wyeth’s products ...